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Summary
Background and objectivesNephrotic syndrome (NS) is a raremanifestation of IgA nephropathy (IgAN). Clinical
characteristics and long-term outcomes of this condition have not yet been explored.
Design, setting, participants, & measurements A multicenter observational study was conducted between
January 2000 and September 2010 in 1076 patients with biopsy-proven IgAN from four medical centers in Korea.
The primary outcome was a doubling of the baseline serum creatinine concentration.
ResultsOf the 1076 patients, 100 (10.2%) presentedwith NS; complete remission (CR), partial remission (PR), and
no response (NR) occurred in 48 (48%), 32 (32%), and 20 (20%) patients, respectively. During the median
follow-up of 45.2 months, 24 patients (24%) in the NS group reached the primary endpoint compared with
63 (7.1%) in the non-NS group (P,0.001). The risk of reaching the primary endpoint was signiﬁcantly higher in
the PR (P=0.04) and NR groups (P,0.001) than in the CR group. Among patients with NS, 24 (24%) underwent
spontaneous remission (SR). SR occurred more frequently in female patients and in patients with serum creat-
inine levels#1.2 mg/dl and a.50% decrease in proteinuria within 3months after NS onset. None of the patients
with SR reached the primary endpoint and they had fewer relapses during follow-up.
Conclusions This study demonstrated that the prognosis of NS in IgAN was not favorable unless PR or CR was
achieved. In addition, SR was more common than expected, particularly in patients with preserved kidney
function and spontaneous decrease in proteinuria shortly after NS onset.
Clin J Am Soc Nephrol 7: 427–436, 2012. doi: 10.2215/CJN.04820511
Introduction
IgA nephropathy (IgAN) is the most common form of
GN worldwide, comprising 45% of all primary GN
cases (1,2). Many studies report that 30%–40% of pa-
tients with IgAN reach ESRD within 20 years from
apparent disease onset, underscoring that IgAN is
not a benign condition (2–4).
In most cases, initial manifestations of IgAN are
recurrent episodes of gross hematuria that usually arise
after upper respiratory tract infections and asymp-
tomatic microscopic hematuria with or without mild
proteinuria. Fewer than 10% of patients present with
uncommon features such as ARF or nephrotic syn-
drome (NS) (5,6). In particular, NS occurs in only 5%
of all patients with IgAN (2). Because IgAN is a slowly
progressive type of GN and most patients exhibit nor-
mal kidney function at the time of diagnosis, nephrotic
range proteinuria is usually indicative of severe glo-
merular damage in advanced decompensated kidney
failure (7). Conversely, clinical features of NS, such as
heavy proteinuria, generalized edema, and hypoalbu-
minemia, can be observed in some patients with nor-
mal kidney function. This rare condition is reported to
behave similarly to minimal change disease (MCD)
(8,9). Accordingly, corticosteroids are often prescribed
for IgAN patients with NS because of the favorable
steroid responsiveness in MCD (9–11). Most studies re-
garding this unusual condition were published more
than two decades ago. In addition, not all cases of NS
in IgAN are caused by MCD, and corticosteroid ther-
apy does not always lead to the resolution of heavy
proteinuria (12–14). Furthermore, we found that spon-
taneous remission (SR) of NS in IgAN was common
in a recent study (14). However, we were unable to
identify factors associated with SR in our single-center
study because of the small number of patients in our
sample. To address these issues, we conducted a mul-
ticenter, retrospective, observational study of 1076 pa-
tients with biopsy-proven IgAN. The aims of this study
were to examine the clinical features and long-term
outcome of IgAN with NS, and to delineate factors
associated with SR among NS patients.
Materials and Methods
Patients
The study sample comprised 1076 patients with
biopsy-proven IgAN who were recruited between
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January 2000 and September 2010 from four medical cen-
ters in Korea. All patients had deﬁnite pathologic data
with predominant mesangial deposition of IgA with at
least 1+ on immunoﬂuorescent staining and electron-dense
deposits within the mesangium detected by electron mi-
croscopy. Exclusion criteria were as follows: aged ,18
years (n=26); crescentic GN (n=2); follow-up duration ,6
months (n=15); estimated GFR (eGFR) ,30 ml/min per
1.73 m2 (n=29); malignancy (n=3); systemic inﬂammation,
such as Henoch–Schönlein purpura (n=6); or chronic ad-
vanced liver disease (n=10).
Data Collection
Using medical records, demographic and clinical data
were reviewed retrospectively for age, sex, medical history,
presenting symptoms, medications, follow-up duration, time
to remission of NS, time to doubling of the baseline serum
creatinine levels and ESRD, and responsiveness to treatment.
Laboratory data included 24-hour urinary protein excretion,
urinary protein-to-creatinine ratio (UPCR), and serum cre-
atinine, albumin, and total cholesterol levels. The eGFR was
calculated using the four-variable Modiﬁcation of Diet in
Renal Disease study equation (15).
Data for baseline 24-hour urinary protein excretion were
available for all 100 patients with NS and for 469 patients
with non-NS and UPCR .1.0. Among the remaining 416
patients with non-NS and UPCR #1.0, 238 underwent 24-
hour urine collection 52.5614.2 days after diagnosis. How-
ever, 178 patients (18.1%) with UPCR #0.5 did not have
24-hour urine collection data. Therefore, data for 24-hour
proteinuria were available for 807 patients (81.9%).
Renal pathology data included information on the num-
ber of glomeruli and the presence of global or segmental
sclerosis, foot process effacement, mesangial hypercellularity,
endocapillary proliferation, tubular atrophy, and interstitial
ﬁbrosis. All cases were graded using the Haas (16) and the
Oxford classiﬁcation systems (17).
Definitions
The deﬁnitions for each term in this study were identical
to deﬁnitions used in our previous study (14). NS was de-
ﬁned as the presence of generalized edema, heavy protein-
uria of .3.5 g/d, hypoalbuminemia ,3.5 g/dl, and/or
hypercholesterolemia. Complete remission (CR) was de-
ﬁned as the absence of proteinuria (UPCR ,0.3 g/g) along
with the disappearance of edema, normalization of all bio-
chemical ﬁndings, and lack of worsening of renal function.
SR was used to indicate CR of NS without the use of cor-
ticosteroids or other immunosuppressive agents. Partial
remission (PR) was deﬁned as a .50% reduction in pro-
teinuria from baseline to ,3.5 g/d. No response (NR) was
deﬁned as a ,50% reduction in proteinuria or an increase
in proteinuria with or without renal deterioration. Relapse
was deﬁned as the reappearance of signiﬁcant proteinuria,
deﬁned as .1.0 g/d and/or .3+ urinary albumin by the
dipstick test.
Study Endpoints
The primary outcome was a doubling of the baseline
serum creatinine concentration; secondary outcomes in-
cluded ESRD and death. A doubling of serum creatinine
levels was deﬁned as a sustained, greater than two-fold in-
crease in serum creatinine levels for at least three consec-
utive measurements.
Statistical Analyses
Variables with normal distributions were expressed as
mean 6 SD and were compared using the t test or one-
way ANOVA. Kolmogorov–Smirnov tests were used to
analyze the normality of the distribution of parameters.
Nonparametric variables were expressed as median with
range and compared using the Mann–Whitney test or
Kruskal–Wallis test. Categorical variables were expressed
as percentages and compared using the chi-squared test.
Cumulative survival curves were derived using the Kaplan–
Meier method, and differences between survival curves
were compared using the log-rank test. Five patients who
were lost to follow-up were considered “censored” in the
analyses. A Cox proportional hazards model was used to
identify independent factors for the development of pri-
mary or secondary endpoints and SR. Statistical signiﬁcance
was determined as P,0.05. SPSS software (version 15.0;
SPSS Inc, Chicago, IL) was used for all statistical analyses.
Results
Baseline Characteristics
A ﬂow diagram describing the patient sample and
exclusions is shown in Figure 1. Baseline characteristics
of the 985 patients who met the inclusion criteria are
shown in Table 1. Among these patients, NS occurred in
100 (10.2%), with 93 having generalized edema as the ﬁrst
presenting symptom and undergoing renal biopsy within
an average of 7 days of symptom onset (1–17). The remain-
ing seven patients initially had microscopic hematuria
with minimal proteinuria (UPCR # 0.5 g/g) but presented
with acute NS onset during follow-up. Of these patients,
four underwent renal biopsy at NS onset, whereas biopsies
were performed in the other three patients at 408, 983, and
1021 days before NS development.
There were 13 patients who had a UPCR .3.0 g/g in the
non-NS group. Among them, three patients had a protein-
uria .3.0 g/d (but ,3.5 g/d). They were categorized as
non-NS because they did not exhibit other NS features
such as hypoalbuminemia, edema, or hypercholesterol-
emia. We also conﬁrmed that nephrotic proteinuria was
not ascribed to hypertensive nephrosclerosis because BP
was well controlled in 20 patients with a prior history
of hypertension and pathologic ﬁndings suggesting that
hypertensive nephrosclerosis were not found in all NS
patients.
Although hyperlipidemia is common in NS, not all
patients with NS have hyperlipidemia as previously sug-
gested (18). In our study, only six patients with NS (6%)
had total cholesterol levels ,200 mg/dl. However, they
had edema and hypoalbuminemia and thus were consid-
ered to have NS.
Clinical Features of Patients with NS According to
Clinical Response
Table 2 shows the clinical features of patients with IgAN
with NS according to clinical response. CR was achieved
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in 48 patients (48%) and PR in 32 patients (32%). However,
20 patients (20%) exhibited minimal response or disease
progression (NR).
Among patients with NS, 24 (24%) achieved SR without
the use of corticosteroids. In these patients, corticosteroids
were not immediately administered because rapid and
continuous reductions in proteinuria (.50%) occurred af-
ter NS onset. In addition, some had uncontrolled diabetes
(n=2), gastric ulcers (n=2), pulmonary tuberculosis (n=1),
severe osteoporosis (n=2), or hepatitis B infections (n=1).
Six patients in the PR group and ﬁve in the NR group did
not receive corticosteroids because of uncontrolled diabe-
tes (n=1, PR), gastric ulcers with bleeding (n=1, PR),
hepatitis B infections (n=2, PR; n=4, NR), or disagreement
over the use of steroid treatment (n=2, PR; n=1, NR).
As shown in Table 2, no signiﬁcant differences in sex,
age, BP, serum creatinine levels, or 24-hour proteinuria
were observed among the four subgroups. However, class
I or II lesions according to the Haas classiﬁcation were
more common in patients with CR than in those with PR
or NR (P=0.001), whereas SR occurred in all subclasses of
IgAN (Supplemental Table 1).
Long-Term Clinical Outcomes
During the median follow-up of 45.2 months (range, 9.0–
134.6), 24 patients (24%) in the NS group reached the
Figure 1. | Flow diagram of patient progress and outcomes. From January 2000 through September 2010, IgA nephropathy was diagnosed in
1076 patients, and 100 presented with nephrotic syndrome. FU, follow-up; eGFR, estimated GFR; NS, nephrotic syndrome; CR, complete
remission; SR, spontaneous remission; IS, complete remission with the use of immunosuppressant; PR, partial remission; NR, no remission or
disease progression.
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primary endpoint compared with 63 (7.1%) in the non-NS
group (P,0.001). In addition, 11 patients (11.0%) in the NS
group progressed to ESRD and two (2.0%) died, compared
with 33 (3.7%) with ESRD and 8 (0.9%) deaths in the non-
NS group (P,0.001) (Figures 1 and 2A). Increased risks of
primary and secondary outcomes were consistently ob-
served for the NS group by different multivariate analysis
models (Supplemental Table 2).
As shown in Table 3 and Figure 2B, in NS patients, the
risk of reaching the primary endpoint was signiﬁcantly
higher in the PR group (hazard ratio [HR], 14.49; 95% con-
ﬁdence interval [CI], 1.14–183.76; P=0.04) and NR group
(HR, 215; 95% CI, 15–2983; P,0.001) than in the CR group.
In addition, nine patients in the NR group reached ESRD
compared with two in the PR group (HR, 7.14; 95% CI,
2.61–19.48; P,0.001), whereas ESRD did not occur in the
CR group (Supplemental Table 3). When we re-analyzed
the data using an eGFR cutoff of ,60 ml/min per 1.73 m2
instead of serum creatinine #1.2 mg/dl, the results of
these two analyses were similar (Supplemental Table 4).
Because of concerns about lower eGFR in female patients
for the same creatinine levels compared with male pa-
tients, we tested an interaction between sex and eGFR.
However, there was no signiﬁcant interaction between
the two variables (data not shown).
Interestingly, no patients with SR reached the primary or
secondary endpoints (Supplemental Table 3). SR occurred
mainly within 6 months after NS onset. The median times
to SR and .50% reduction in proteinuria were 154 and
52 days, respectively. Only two patients (8.3%) in the
SR group experienced relapse of NS, compared with
11 (45.8%) in the immunosuppressive agent group
(P,0.001). Of the two relapsed patients in the SR group,
one re-entered SR after 6 months without corticosteroids,
whereas the other exhibited a spontaneous decrease in pro-
teinuria shortly after the relapse with a UPCR of 1.49 g/g at
the ﬁnal visit.
Clinical Predictors of SR or CR in NS Patients with IgAN
We further investigated the factors associated with SR of
NS in patients with IgAN. A .50% decrease in proteinuria
within 3 months after NS onset (HR, 8.37; 95% CI, 3.12–
22.40; P,0.001), serum creatinine #1.2 mg/dl (HR, 4.85;
95% CI, 1.21–19.39; P=0.02), and female sex (HR, 3.81; 95%
CI, 1.39–10.45; P=0.009) were associated with a signiﬁ-
cantly increased likelihood of SR in multivariate Cox re-
gression analysis adjusted for age, mean arterial pressure,
and pathologic ﬁndings (Table 4).
We also examined factors associated with all CR (achieved
by immunosuppressive agents or conservative treatment
only). In addition to a .50% decrease in proteinuria within
3 months, more favorable histologic ﬁndings by both Haas
and Oxford classiﬁcation were associated with CR (Supple-
mental Table 5).
Discussion
To date, NS has not been well characterized in patients
with IgAN. Most previous studies involved only small
numbers of patients with MCD-like features who had
minimal histologic lesions and normal renal function (8,19).
Table 1. Baseline characteristics of patients with IgA nephropathy
All Patients
(N=985)
Nephrotic
Syndrome
(n=100)
Non-Nephrotic
Syndrome
(n=885)
P
Age (yr) 37.7612.8 39.5615.0 37.4612.5 0.12
Male sex, n (%) 459 (46.6) 44 (44.0) 412 (46.6) 0.83
Hypertension, n (%) 125 (12.7) 20 (20.0) 105 (11.9) 0.03
Diabetes, n (%) 14 (1.4) 4 (2.9) 10 (1.1) 0.08
Hepatitis B surface antigen positivity, n (%) 31 (3.1) 7 (7.0) 24 (2.7) 0.04
Systolic BP (mmHg) 123.7634.8 131.9615.1 122.1634.8 0.01
Diastolic BP (mmHg) 76.868.9 81.1610.3 76.268.7 ,0.001
Mean arterial BP (mmHg) 92.4614.3 98.0610.9 91.8614.5 ,0.001
Laboratory measurements
24-h protein excretion (g/d) 1.31 (0.0–16.10) 5.80 (3.67–16.10) 1.5 (0.0–3.40) ,0.001
random UPCR (g/g) 1.05 (0.01–18.20) 5.74 (3.50–18.20) 0.98 (0.01–3.74) ,0.001
SCr (mg/dl) 1.060.6 1.260.4 0.960.3 ,0.001
eGFR (ml/min per 1.73 m2) 84.1639.1 69.4617.5 88.5632.5 ,0.001
serum albumin (g/dl) 4.160.7 2.860.6 4.260.5 ,0.001
total cholesterol (mg/dl) 190.5651.3 267.0676.2 181.8639.1 ,0.001
Follow-up duration (mo) 45.2 (9.0–134.6) 43.1 (9.0–107.8) 47.1 (10.0–134.6) 0.06
Treatments, n (%) ,0.001
none 197 (20.0) 0 (0.0) 197 (22.3)
ACEi or ARB 778 (79.0) 95 (95.0) 683 (77.2)
dual blockades 10 (1.0) 5 (5.0) 5 (0.5)
corticosteroids 144 (14.6) 65 (65.0) 79 (8.9)
All data are expressed as mean 6 SD and median (range). UPCR, urinary protein-to-creatinine ratio; SCr, serum creatinine;
eGFR, estimated GFR; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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Accordingly, corticosteroids were commonly prescribed,
with most patients responding well to this treatment.
However, NS may occur in any subclass of IgAN and cor-
ticosteroids do not consistently result in complete resolu-
tion of heavy proteinuria (11,13,14,20). These ﬁndings
suggest that MCD is not entirely responsible for the de-
velopment of NS in patients with IgAN. In this study, we
conducted an in-depth review of more than 1000 cases of
IgAN from four tertiary medical centers in Korea, and re-
cruited 100 patients who had NS features. To our
Figure 2. | Effect of clinical response on renal survival. The primary endpoint was a doubling of the baseline serum creatinine. (A) Risk of
reaching the primary outcome was significantly higher in the NS group than in the non-NS group (P,0.001). (B) Patients with NS attaining CR
or PR had a favorable outcome compared with patients with NR (P,0.001). NS, nephrotic syndrome; CR, complete remission; PR, partial
remission; NR, no remission or disease progression.
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knowledge, our study reports the largest sample of pa-
tients with this rare condition to date.
One major ﬁnding in this study was that the prognosis of
NS in patients with IgAN was not superior to that of
patients with classic IgAN. However, this ﬁnding should
be interpreted with caution because most patients who
reached the study endpoint were in the NR group. In fact,
only two patients in the CR group reached the primary
outcome without developing ESRD. Renal survival in this
group was excellent, with a 7-year survival of 95.8%
(Figure 2). In addition, we note that patients who attained
PR also had favorable outcomes. In these patients, the risk
reduction for the primary outcome was much greater than
those in the NR group. The importance of PR has been
suggested for various glomerulopathies (1,21,22). In par-
ticular, Reich et al. indicated that patients with IgAN who
initially presented with proteinuria .3 g/d and achieved
PR (,1 g/d) had similar outcomes to patients with persis-
tent proteinuria of ,1 g/d during follow-up and also had
superior prognoses to patients who never achieved remis-
sion (1). However, that study included all patients with
IgAN irrespective of kidney function, even those with se-
rum creatinine concentrations up to 8.31 mg/dl. In addi-
tion, whether patients with NS were included is uncertain.
Therefore, heavy proteinuria in some of the included pa-
tients was presumably because of advanced kidney disease
from IgAN per se. In contrast, we included only patients
who had typical features of NS with eGFR$30 ml/min per
1.73 m2. This unique subgroup of patients should be
analyzed separately because few studies outline the thera-
peutic implications of this rare condition, although cortico-
steroids appeared to be favored with inconsistent results
(9,11,13,20), Nevertheless, our ﬁndings are in line with
those of previous studies suggesting the importance of
remission, whether complete or partial, to improve renal
outcomes.
Another valuable ﬁnding of our study was that SR was
more common than expected, with 24% of NS patients
experiencing SR. More than 20 years after the publication of
two case reports of SR in NS with IgAN (23,24), we recently
reported that 5 (20.8%) of 24 patients with IgAN present-
ing with NS entered SR shortly after NS onset (14). How-
ever, this was a single-center study with a limited number
of patients. The results presented here were derived from a
larger sample of patients, allowing comprehensive analy-
ses to characterize these patients and to identify factors
associated with SR. Our results support our earlier ﬁnd-
ings that SR was common, with many SR patients exhibit-
ing spontaneous decreases in proteinuria within 1–3
months after NS onset. All patients with SR had excellent
outcomes without progression.
Interestingly, in this study, SR occurred irrespective of
IgAN subclass, which we had observed in our earlier study
(14). For example, 11 patients who had a Haas classiﬁcation
of IV or V experienced SR. The pathologic ﬁndings in these
patients did not correspond with the deﬁnition of MCD.
Moreover, diffusely effaced foot processes, which are a typ-
ical feature of MCD, were observed in only 45.8% of pa-
tients. These ﬁndings suggest that MCD cannot explain all
cases of IgAN with NS. As suggested previously, nephrotic
range proteinuria in patients with IgAN might be caused by
other forms of NS or accompanying GN (6,14).
Several shortcomings of this study should be discussed.
First, no consensus exists regarding whether NS in IgAN is
an MCD with incidental IgA deposition or a true IgAN.
However, the results of several studies suggest that the
former is more likely when biopsy ﬁndings show a class I
lesion by the Haas classiﬁcation, diffuse foot process
effacement, and trace or approximately 1+ IgA deposition
(10,25). This study included only four patients who met
these criteria. Although they were excluded from the anal-
yses, our results remained unaltered (data not shown). In
addition, concomitant C3 deposition was found in 91 pa-
tients (91%) with NS (Supplemental Table 1). Because C3
deposition is commonly found in IgAN (26), together these
ﬁndings favor a diagnosis of true IgAN for our study par-
ticipants. Second, although most previous studies recom-
mended corticosteroid therapy as used for MCD (27), our
observational study had no preset indications for treating
NS in patients with IgAN. Accordingly, treatment differed
depending on individual physician preferences. Therefore,
worse outcomes in patients with NR might be attributed to
relatively shorter durations of corticosteroid therapy or
early treatment discontinuation. Nevertheless, NR patients
exhibited no signs of improvement despite receiving cor-
ticosteroids for at least 3 months. Considering the in-
consistent results from several studies regarding steroid
responsiveness in patients with IgAN complicated by
NS (9,11,13,20), a more well designed, prospective, ran-
domized, controlled study is required to address this un-
resolved issue. Third, as mentioned in our previous study,
because most NS patients were treated with renin–
angiotensin system (RAS) blockers, the identiﬁcation of
SR may be technically inaccurate. However, complete disap-
pearance of heavy proteinuria is very unlikely to be ach-
ieved by RAS blocker treatment alone because RAS blockers
decrease proteinuria by 30%–40% from baseline at best,
with a varying extent of decrease (28,29). Fourth, the me-
dian observation period of this study was 45.2 months
(range, 9.0–134.6). Therefore, we were unable to determine
if patients in remission had favorable long-term outcomes.
However, two patients who achieved CR after corticoste-
roid therapy developed a two-fold increase in serum cre-
atinine levels at 7.7 and 9.0 years after the ﬁrst remission.
Given the very slow development of IgAN, a longer pe-
riod of observation is required to validate our ﬁndings.
Fifth, our results may not be extrapolated to other ethnic
populations because a prior study suggested a geograph-
ical variability in long-term outcomes of IgAN (30). Fi-
nally, there were many covariates in some multivariate
models. However, these are previously known to be
strongly associated with outcomes, and thus were in-
cluded in the models to conﬁrm our ﬁndings.
In conclusion, we demonstrated that IgAN patients with
NS had worse renal outcomes than did those without NS.
At the very least, PR should be achieved to delay the
progression of kidney disease, because patients who un-
derwent remission had far better outcomes than patients
who never achieved remission. These ﬁndings suggest that
achieving remission, whether complete or partial, is of
paramount importance in heavily proteinuric patients to
improve renal survival, irrespective of glomerular disease
type. In addition, SR of NS is common, particularly in patients
with a spontaneous substantial decrease in proteinuria
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shortly after NS onset, and with preserved kidney function.
Our novel ﬁndings may have therapeutic implications for
the management of NS in patients with IgAN.
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